Lentigen and Evrogen Enter License Agreement
News Jan 31, 2006
Such technologies will enable the Company to expand customer service opportunities related to the design and manufacturing of its proprietary lentiviral vectors.
Access to these fluorescent technologies, including TurboGFP (green fluorescent protein), phi YFP (yellow) and J-Red (Red) will allow Lentigen to create lentiviral vectors with a multiple of fluorescent possibilities for customers who purchase its custom lentiviral vectors.
"This license agreement represents another important offering for Lentigen customers," remarked Dr. Boro Dropulic, Founder and CEO of Lentigen.
"These technologies expand the opportunities now available to Lentigen and our customers by providing additional research capabilities to our lentiviral vector technology."
"Lentigen aims to license additional technologies which add to the usefulness of our lentiviral vectors for both research and therapeutic purposes."
Dr. Sergey Lukyanov, Evrogen's Chief Scientific Officer, said, "We are pleased to have established the license agreement and collaboration with Lentigen Corporation to further expand the adoption and availability of novel fluorescent protein technology for life science researchers interested in new lentiviral products and related services."
A team led by Johns Hopkins Medicine researchers says it has identified two protein biomarkers in urine that may one day be used to better diagnose acute interstitial nephritis, an underdiagnosed but treatable kidney disorder that impairs renal function in the short term and can lead to chronic kidney disease, permanent damage or renal failure if left unchecked.READ MORE